Astrazeneca Says Imfinzi Plus Tremelimumab Combination Did Not Meet Primary Endpoint of Progression-Free Survival Compared to Chemotherapy; Mystic Trial Continues as Planned to Assess Additional Primary Endpoints of Overall Survival